LONDON — The FTSE 100 has risen by 25% over the last year, and many top shares are beginning to look quite expensive.
I’m on the hunt for companies that still look cheap, based on their long-term earnings potential. To help me hunt down these bargains, I’m using a special version of the price to earnings ratio called the PE10, which is one of my favorite tools for value investing.
The PE10 compares the current share price with average earnings per share for the last ten years. This smoothes out any short-term volatility and lets you see whether a company looks cheap compared to its long-term earnings.
Today, I’m going to take a look at the PE10 for RSA Insurance Group (LSE: RSA )
Is RSA Insurance Group a buy?
RSA’s share price has dropped by nearly 20% since February, when the firm announced a 33% cut to its final dividend, and said that the interim dividend would also be cut by a similar percentage.
However, despite the cuts, RSA’s prospective dividend yield of 5.3% is still one of the highest in the FTSE 100 — so is it a buy?
5 Best Tech Stocks For 2014: Cytomedix Inc (CMXI)
Cytomedix, Inc. (Cytomedix), incorporated in April 29, 1998, is a regenerative therapies company marketing and developing products within the United States and internationally .The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company is a commercial operation, and a robust clinical pipeline representing a logical extension of its commercial technologies in the evolving field of regenerative medicine. Cytomedix primarily operates in the United States. Its commercial offerings are centered on its point of care platform technologies for the safe and efficient separation of blood and bone marrow to produce platelet based therapies or cell concentrates.
The Company markets and selsl two distinct platelet rich plasma (PRP) technologies, the AutoloGel System for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) Sytem in orthopedic and cardiovascular markets. It s clinical pipeline includes the ALDH, which are cell-based therapies (Bright Cells). In February 2012, the Company acquired Aldagen, Inc.
The AutoloGel System
The AutoloGel System is a point of care device for the production of a platelet based bioactive therapy derived from a small sample of the patient’s own blood. Using the patient’s own platelets as a therapeutic agent, AutoloGel harnesses the body’s natural healing processes to deliver growth factors, chemokines and cytokines known to promote angiogenesis and to regulate cell growth and the formation of new tissue.
Angel Product Line
The Angel concentrated Platelet Rich Plasma (cPRP) System is a multi-functional cell separation device which produces concentrated platelet rich plasma for use in the operating room and clinic and is used in a range of orthopedic and cardiovascular indications. Similar to the AutoloGel System, the Angel System is a point of care d evice for the production of a concentrated, aseptic platelet! -based bioactive therapy derived from a small sample of the patient’s own blood. The resulting cPRP is applied at the site of injury to promote healing. The Angel product line also includes ancillary products such as phlebotomy and applicator supplies and activAT. activAT is designed to produce autologous thrombin serum from platelet poor plasma and is sold exclusively in Europe and Canada, where it provides a safe alternative to bovine-derived products.
ALDHbr Cell Technology and Development Pipeline
The ALDHbr (Bright Cell) technology is an approach to cell-based regenerative medicine and a logical extension of its commercial technologies in the evolving regenerative medicine market, with potential clinical indications in markets with unmet medical needs such as peripheral arterial disease and ischemic stroke. The Bright Cell technology is in that it utilizes an intracellular enzyme marker to facilitate fractionation of essential regenerative cells from a patient’s bone marrow. The bone marrow fractionation process identifies and isolates active stem and progenitor cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation.
The Company’s lead product candidate, ALD-401, is an autologous preparation of Bright Cells for the post-acute treatment of ischemic stroke. ALD-401 is being evaluated in the RECOVER-Stroke clinical study, an ongoing 100-patient, double-blind, placebo-controlled Phase 2 study in patients with unilateral, cerebral ischemic stroke with an NIH stroke scale score of less than 22. An additional product candidate, ALD-301, is in clinical development for peripheral arterial disease (PAD), a condition causing reduced flow of blood and oxygen to muscles in the leg. It has completed a Phase 1/2 study of autologous ALD-301 in critical limb ischemia ( CLI), a late stage condition caused by PAD. The Phase 2 PACE! (Patient! s with Intermittent Claudication Injected with ALDH Bright Cells) study is an 80 patient, double-blind, placebo-controlled clinical trial intended to demonstrate the safety and efficacy of ALD-301 (Bright Cells) in patients diagnosed with IC.
The Company competes with Harvest Technologies (a subsidiary of Terumo), Biomet, Arteriocyte, and Arthrex.
- [By James E. Brumley]
To give credit where it’s due, Cytomedix, Inc. (OTCBB:CMXI) and Baxter International Inc. (NYSE:BAX) have both helped shape the landscape of the hemostasis (bleeding control) market with their products, AutoloGel and TISSELL, respectively. Arch Therapeutics Inc. (OTCBB:ARTH) has proverbially taken their concepts “up a notch”, however, and its direct solution to a problem that CMXI and BAX can’t quite solve may make ARTH the hottest trading candidate in the hemostasis space.
- [By Bryan Murphy]
When traders think of post-surgical wound management stocks, they may first think of names like Cytomedix, Inc. (OTCBB:CMXI) or Alliqua Inc. (OTCMKTS:ALQA). And well they should. Both companies have something of a history in the arena. ALQA is the purveyor of SilverSeal and Hydress antibiotic bandages, while CMXI is the developer of the AutoloGel system, which induces an affected patient’s on body to do what it’s supposed to do if there’s a wound that won’t heal. Cytomedix also makes the Angel platelet-rich plasma (PRP) delivery system. There’s a relatively new name to add to the list of game-changing stocks in wound-management industry, however…. Arch Therapeutics Inc. (OTCBB:ARTH). The company is developing – well, has developed – a product called AC5 that nips post-surgical bleeding in the bud, largely negating the need for other post-surgical bleeding-control measures.
5 Best Tech Stocks For 2014: Nice Systems Ltd (NICE)
NICE-Systems Ltd. (NICE), incorporated on September 28, 1986, is a provider of solutions that enable enterprises and security organizations to extract insight from interactions, transactions and surveillance to drive business performance and ensure safety and security. Its solutions enable companies and public organizations to capture, manage, analyze and impact unstructured interaction, as well as transactional data, enabling such entities to comply with internal and governmental regulations, improve business and operational performance and address security threats while increasing situational awareness. Unstructured content includes cross-channel analysis of phone calls, chat, instant messaging and e-mail interactions to contact centers, trading floors, branches, home agents and back offices, phone calls to emergency service providers and first responders, video captured by closed circuit cameras, radio communications between emergency services’ and first responders’ personnel, Internet sessions, e-mail and instant messaging and security management solutions for command and control centers. In May 2010, the Company acquired Lamda Communication Networks Ltd.
On January 11, 2010, NICE completed the acquisition of certain assets and liabilities of Orsus Solutions Limited and certain subsidiaries of Orsus. On August 31, 2009, NICE and certain subsidiaries of NICE completed the acquisition of the voting securities of certain subsidiaries of Fortent, Inc. (Fortent). On August 31, 2009, NICE completed the acquisition of Hexagon System Engineering Ltd. (Hexagon). On June 17, 2009, the Company completed the acquisition of Syfact.
The Company’s products include NICE SmartCenter, NICE Perform Interaction Recording, NICE Perform eXpress (NPX), NICE Quality Management, NICE Interaction Analytics, NICE Real-Time Guidance, NICE Packaged Business Solutions, NICE Feedback, NICE IEX Workforce Management, Performance Manager, Network Embedded Logger and NiceCall Focus III. It also incl! udes Actimize Fraud Prevention Suite, Actimize Anti-Money Laundering Suite, Actimize Brokerage Compliance Suite, Actimize Enterprise Risk Case Manager, Mirra IV, NICE Inform, NiceVision Net, NiceVision ControlCenter, NiceVision Analytics, NiceVision Digital, NiceVision SafeRoute, NICE Situator, FAST alpha Silver, NiceTrack.
NICE SmartCenter leverages the synergies of the combined capabilities of NICE Perform, NICE Quality Management, NICE Interaction Analytics, NICE Feedback, IEX TotalView and Performance Manager. NICE Perform Interaction Recording records customer interactions with contact center agents, financial trading floors, investment banking and enterprises, with a separate suite of applications for contact centers and investment banking, including for organizations that have a relatively small number of input channels. NICE Perform eXpress (NPX) brings the capabilities of Nice Perform into a single box, low TCO solution based on commercial hardware for small businesses or small systems. NICE Quality Management delivers tools for implementing a multifaceted quality program encompassing agents, supervisors, evaluators and managers.
NICE Interaction Analytics utilizes a multi-dimensional analysis approach to analyze customer interactions across communication channels and provide automated business insight and root cause analysis based on speech analytics, e-mail and chat analysis, call flow analysis, screen content analysis and integration with customer relationship management (CRM) data. NICE Real-Time Guidance leverages interaction analytics in order to provide recommendations to the agent in real-time during a phone or chat interaction with a customer, popping up contextually relevant instructions to the agent within call-out windows.
NICE Packaged Business Solutions is a set of out-of-the-box solutions designed to address common contact center challenges, including Customer Churn Reduction, S ales Effectiveness, Customer Experience, Marketing Effective! ness, Col! lections Optimization, Quality Optimization, such as First Contact Resolution and Average Handling Time. NICE Feedback is a solution for collecting real-time customer feedback after a call or any other type of interaction with the organization. NICE IEX Workforce Management forecasts customer interactions, schedules agents with appropriate skills to manage and optimize level of customer service and resources, measures agent and team performance and supports managing overall contact center performance
Performance Manager maps enterprise business objectives to group and individual goals, tracks and reports performance. Network Embedded Logger offers a Linux based voice over Internet protocol (VoIP) Logger embedded in Cisco routers, suitable for branch recording with NICE Perform. NiceCall Focus III provides a voice recording system for organizations that have a relatively small number of input channels and a cost-effective solution for branch recording (TDM only ) with centralized storage. Actimize Fraud Prevention Suite is a suite of focused cross-channel fraud prevention solutions, available individually or as an integrated whole, used in both real-time and batch processing to detect and prevent the fraud.
Actimize Anti-Money Laundering Suite is an end-to-end suite of solutions that are available individually or as an integrated whole used to monitor and identify suspicious activities for customers and facilitate regulatory compliance processes. Actimize Enterprise Risk Case Manager is a centralized platform for holistic case and alert management that enables an enterprise-wide approach to risk and compliance operations management. Mirra IV provides small recording system that is suited to simple recording applications, in which it can record up to 48 channels of voice traffic from a variety of analog and digital interfaces. NICE Inform provides information management solution for management of multimedia interaction s for security command and control centers, enables effectiv! e managem! ent of multimedia incident information from various sources, for faster incident reconstruction, greater insight and improved response.
NiceVision Net provides a complete solution for Internet protocol (IP) video security, including encoders, decoders and network video recorders. NiceVision ControlCenter provides a control room management and network-based digital video matrix. NiceVision Analytics provides a set of video content analytics applications for automated detection of threats, safety and operational related events. NiceVision Digital provides a portfolio of digital video recorders for different capacities and performance requirements. NiceVision SafeRoute provides a solution for mobile video surveillance onboard public transport vehicles. FAST alpha Silver provides digital video monitoring and recording solution for large to mid-size applications. NiceTrack provides interception, delivery, monitoring, collection and advanced analysis of telecommunic ation interactions.
The Company competes with Aspect Software, Inc., Autonomy Corp., Cybertech International, eLoyalty, Genesys Telecommunicatons, Nexidia, Verint Systems Inc., ACI Worldwide, FICO, Mantas, Inc., Norkom Group plc, Oracle Corporation, SAS Institute Inc., Sungard Data Systems Inc., ASC Telecom, AudioSoft, Redbox Recorders, Bosch, Genetec Inc., IndigoVision, Milestone Systems A/S, ONSSI, Schneider Electric, Atis, ETI, JSI Telecom, Pen-link Ltd., SS8 Networks, Inc. and Trovicor.
- [By Lee Jackson]
NICE Systems Ltd. (NASDAQ: NICE) is the worldwide leading provider of software solutions that enable organizations to take the next best action in order to improve customer experience and business results, ensure compliance, fight financial crime and safeguard people and assets. NICE’s solutions empower organizations to capture, analyze and apply, in real time, insights from both structured and unstructured Big Data. Investors are paid a 1.3% dividend. J.P. Morgan has a $46 price target, while the consensus sits at $44. The stock closed Tuesday at $42.20 a share.
- [By Monica Gerson]
Wi-LAN (NASDAQ: WILN) today announced that its Board of Directors has initiated a process to explore and evaluate a broad range of strategic alternatives for the Company to enhance shareholder value. To read the full news, click here. MannKind (NASDAQ: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for AFREZZA® (insulin human [rDNA origin]) Inhalation Powder. To read the full news, click here. lululemon athletica (NASDAQ: LULU) today announced that Tara Poseley has been appointed to its Senior Leadership Team as Chief Product Officer. To read the full news, click here. Nice Systems (NASDAQ: NICE) reported a drop in its third-quarter profit. To read the full news, click here.
Posted-In: Bank of America FOMC US Stock FuturesNews Eurozone Futures Pre-Market Outlook Markets
- [By Traders Reserve]
While J.P. Morgan (JPM) lowered their IT spending forecast for 2013, it sees a 3.6% growth on the horizon in 2014. That bodes well for NICE Systems (NICE) which provides solutions for capturing and analyzing customer interactions across communication channels such as phone, surveys, email and the Web—otherwise known as a Big Data platform.
- [By Roberto Pedone]
Nice Systems (NICE) provides software solutions that deliver insights by capturing and analyzing mass quantities of structured and unstructured data in real time from multiple sources such as interactions, transactions and surveillance. This stock closed up 2.1% to $38 in Wednesday’s trading session.
Wednesday’s Volume: 430,000
Three-Month Average Volume: 135,436
Volume % Change: 218%
From a technical perspective, NICE trended modestly higher here back above its 50-day moving average of $37.69 with heavy upside volume. This move is quickly pushing shares of NICE within range of triggering a big breakout trade. That trade will hit if NICE manages to take out some near-term overhead resistance at $38.90 to its three-year high at $39.89 with high volume.
Traders should now look for long-biased trades in NICE as long as it’s trending above its 50-day at $37.69 or above Wednesday’s low of $36.91, and then once it sustains a move or close above those breakout levels with volume that hits near or above 135,436 shares. If that breakout hits soon, then NICE will set up to enter new three-year high territory, which is bullish technical price action. Some possible upside targets off that move are $43 to $45.
5 Best Tech Stocks For 2014: Merck & Company Inc.(MRK)
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women’s health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
- [By Ben Levisohn]
Stocks bounced back from yesterday’s losses–and it was blue chips like International Business Machines (IBM), Johnson & Jonson (JNJ), Caterpillar (CAT), Merck (MRK) and 3M (MMM) that led the market higher.
- [By David Williamson and Michael Douglass]
These two catalysts have caused analyst price targets to jump, with Piper Jaffray coming out and raising its target on the stock to $36; shares currently sit at $28. In this segment from Friday’s Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass discuss Endocyte’s partnership with Merck (NYSE: MRK ) on the drug, as well as just how much blockbuster potential the drug could have, and why even after a near double the stock is filled with upside.
5 Best Tech Stocks For 2014: OncoGenex Pharmaceuticals Inc.(OGXI)
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company?s clinical stage products include Custirsen, a phase III clinical stage product for treatment in men with metastatic castrate-resistant prostate cancer; OGX-427, which is in phase II clinical development stage is designed to inhibit heat shock protein 27; and SN2310 that completed phase I stage of clinical development is designed to evaluate safety in patients with advanced cancer. Its pre clinical stage products include GX-225 that is focused on reducing the production of IGFBP-2 and IGFBP-5; and CSP-9222, lead compound from a family of caspase activators. OncoGenex Pharmaceuticals, Inc. is based in Bothell, Washington.
- [By John McCamant]
2014 is shaping up to be the most important year for OncoGenex Pharmaceuticals (OGXI), and, we believe, it can very well represent a major inflection point for the company with positive Synergy results.
5 Best Tech Stocks For 2014: Dassault Systemes SA (DASTY.PK)
Dassault Systemes SA provides software solutions and consulting services. The Company’s global customer base includes companies primarily in 11 industrial sectors: automotive; industrial equipment; aerospace; consumer goods; consumer packaged goods; energy; high-tech; shipbuilding; life sciences; construction, and business services. It organizes its business and markets its products and services in two types of applications: the Product Lifecycle Management (PLM) market, to support product development, production, maintenance and lifecycle management, and the Mainstream three-dimensional (3D) market, which is primarily focused on product design. Its software applications address a range of products, from apparel, consumer goods, machine parts and semiconductors to automobiles, aircraft, ships and factories. In March 2011, the Company acquired Intercim. In April 2011, the Company acquired Enginuity PLM. On March 31, 2010, it acquired the IBM PLM. On June 8, 2010, the C ompany acquired Exalead, a French company providing Search Platforms and Search-Based Applications (SBA). In June 2010, the Company acquired Geensoft, a provider of embedded systems development solutions.
The Company has developed a software applications portfolio, organized in brands, in order to provide solutions responding to the requirements of product development: Design, Realistic Simulation, Digital Manufacturing and Production, Collaborative Innovation, and Lifelike Experiences. The Company’s principal brands include SolidWorks , CATIA, SIMULIA, DELMIA, ENOVIA and Universal Services.
SolidWorks applications include 3D tools to design, manage, simulate, sustain and communicate. SolidWorks include 3D Design, Data management, Simulation and Environmental assessments. SolidWorks 3D’s include complex part and assembly modeling, production drawing creation, data management, design validation and simulation of motion, f low and structural performance, environmental impact evalu! at! ion and publishing. SolidWorks Data Management solutions enable control over all design information, eliminating concerns about version control or data loss. SolidWorks simulation technology ensures the quality and performance of the design before users commit to production. SolidWorks Sustainability technology enables users to assess the environmental impact of their design to create more sustainable products.
CATIA is the Company’s PLM solution for 3D collaborative creation. CATIA addresses the complete product development process, from early product concept specification through product in service. CATIA V6 is designed to enable the spectrum of next generation collaborative virtual design. Its product portfolio is consists of four main domains, which include systems, shape design, mechanical design and equipment engineering. CATIA Systems captures, manages, and tracks product requirements with traceability, ensuring that early requir emen ts are met accurately all along the product development cycle. CATIA Shape provides a line of surfacing, reverse engineering, and visualization solutions to create, modify, and validate any type of complex shapes and help streamline the transition and collaboration among industrial designers. CATIA Mechanical delivers a collaborative and flexible design environment with concurrent engineering and change management through relational design. CATIA Equipment provides an integrated environment that enables the collaborative detailed design of electronic, electrical, and fluidic systems in context of a virtual product.
SIMULIA provides a scalable portfolio of realistic simulation solutions designed to enable companies across a range of industries to improve product performance, reduce the number of physical prototypes and drive innovation. SIMULIA’s V6 portfolio spans include finite element analysis, multi-physics solutions, optimization analy sis, and simulation lifecycle management. Its finite e! lement! a! nalysis! software companies are able to create and test virtual prototypes of products and processes. Its multi-physics solutions enable companies to reach beyond the boundaries of a single domain. SIMULIA also provides design exploration and optimization technology, enabling designers and engineers to perform rapid trade-off studies of real-world behavior and accelerate product development. SIMULIA offers simulation lifecycle management, based upon the Company’s ENOVIA architecture offering an open collaborative platform for management of simulation data, processes and intellectual property.
DELMIA covers the Company’s PLM digital manufacturing solutions ranging from virtual process definition, workcell set-up, optimization, scheduling, and operation, to maintenance of real-time production systems. DELMIA V6 covers four principal domains, including Manufacturing planning, with 3D process and resource planning tools for creating and optim izing bu ild-to-order and lean production manufacturing systems; plant and resources engineering, with tools to virtually define and optimize manufacturing assets concurrently with manufacturing planning; program and control engineering, to virtually program, validate and simulate manufacturing systems for the virtual commissioning of production facilities, and control and production execution, which offers an accurate virtual production system to enable companies to track real time production activities, perform schedule changes, launch new programs and introduce model changeovers, and schedule maintenance operations.
ENOVIA addresses business process needs across a broad spectrum of industries, managing simple, as well as engineered, complex products. The ENOVIA V6 products are organized by business processes, which include governance, global sourcing, global sourcing, and unified live collaboration. The Governance domain is designed to he lp compan ies launch enterprise new product introductions on! time and! ! on budget! . Governance includes these sub-processes: Requirements Management, Portfolio Configuration, Program Management, Decision Support Business Intelligence, and Compliance. The Global Sourcing domain allows companies to leverage supply chain capabilities throughout the product lifecycle. The IP Lifecycle domain helps eliminate costly product development errors as it is designed to enable improved cross-functional product design, manufacturing planning and performance simulation. The Unified Live Collaboration domain allows companies to deploy product lifecycle processes across the extended enterprise by providing a single, real-time view of information protocol (IP) across all business process domains, collaborative process management capabilities, and a service-oriented architecture that integrates with other enterprise system
The Company competes with Parametric Technology Corporation, ANSYS, Inc., MSC Software Corporation, Oracle Corporation, SAP AG , Siemens PLM Software, Adobe, Altair Engineering, Autonomy, Aveva, Bentley, Google, Intergraph, MathWorks, Nemetschek AG, Right Hemisphere, and Autodesk, Inc.
- [By Markus Aarnio]
Autodesk’s competitors include Adobe Systems (ADBE), Dassault Systemes SA (DASTY.PK), and Parametric Technology Corporation (PMTC). Here is a table comparing these companies.